Convergence Pharmaceuticals Report issue

For profit Phase 2
Founded: Cambridge United Kingdom (2010)
Status: Acquired by Biogen-IDEC (2015)

Organization Overview

First Clinical Trial
2011
NCT01561027
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Convergence Pharmaceuticals, Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

cnv-2197944 (2 trials)

raxatrigine (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 2)

Erythromelalgia (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Radiculopathy (Phase 2)

Trigeminal Neuralgia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 2